

해외 바이오의약품 임상 현황 ('23년 11월 2주)

한국바이오의약품협회, 2023.11.14.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov

- 모니터링 기간: 2023.11.06.~2023.11.12.

- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 6건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05996523	Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer	Biological: PRGN-2009 Drug: Pembrolizumab	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 2	http://clinicaltrials.gov/ct2/show/study/NCT05996523
NCT05948592	Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection	Biological: TP-102 Other: Placebo	Technophage, SA VectorB2B	Phase 2	http://clinicaltrials.gov/ct2/show/study/NCT05948592
NCT05910801	Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Drug: Lenalidomide Procedure: Lumbar Puncture Procedure: Magnetic Resonance Imaging Procedure: Positron Emission Tomography Biological: Tafasitamab Drug: Venetoclax	Academic and Community Cancer Research United National Cancer Institute (NCI)	Phase 2	http://clinicaltrials.gov/ct2/show/study/NCT05910801
NCT05539365	Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer	Biological: Alpha-type-1 Polarized Dendritic Cells Procedure: Biopsy Procedure: Computed Tomography Procedure: Leukapheresis Biological: Pembrolizumab Other: Quality-of-Life Assessment	Roswell Park Cancer Institute	Phase 2	http://clinicaltrials.gov/ct2/show/study/NCT05539365
NCT05291676	Systems Investigation of Vaccine Responses in Aging and Frailty	Biological: Fluzone Biological: Flud	Yale University National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	http://clinicaltrials.gov/ct2/show/study/NCT05291676
NCT05951959	A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma	Drug: Acalabrutinib Drug: Venetoclax Drug: Rituximab	AstraZeneca	Phase 2	http://clinicaltrials.gov/ct2/show/study/NCT05951959

○ 영국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05951959	A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma	Drug: Acalabrutinib Drug: Venetoclax Drug: Rituximab	AstraZeneca	Phase 2	http://clinicaltrials.gov/ct2/show/study/NCT05951959

○ 독일 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05791409	Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL	Drug: Epcoritamab Drug: Venetoclax	Stichting Hemato-Oncologie voor Volwassenen Nederland Nordic CLL Study Group German CLL Study Group	Phase 1 Phase 2	http://clinicaltrials.gov/ct2/show/study/NCT05791409

해외 바이오의약품 임상 현황 ('23년 11월 2주)

한국바이오의약품협회, 2023.11.14.

○ 중국 9건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06120712	A Phase I b Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002) (MIZAR-002)	Biological: GC101 TIL	Shanghai Juncell Therapeutics	Phase 1 Phase 2	https://clinicaltrials.gov/study/NCT06120712
NCT06129955	Pucotenlimab Combined With Lenvatinib as a Neoadjuvant Therapy for Non Clear Cell Renal Cell Carcinoma	Drug: Pucotenlimab Combined With Lenvatinib	Sun Yat-sen University	Phase 2	https://clinicaltrials.gov/study/NCT06129955
NCT06126406	Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) for CEA Positive Advanced Malignant Solid Tumors	Biological: CEA-targeted CAR-T cells	Chongqing Precision Biotech Co., Ltd First Affiliated Hospital of Wannan Medical College	Phase 1	https://clinicaltrials.gov/study/NCT06126406
NCT06114056	A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of Single Intravenous Infusion of JWK007 in Patients With Duchenne Muscular Dystrophy (DMD)	Biological: JWK007 Single intravenous infusion administration	West China Hospital	Phase 1	https://clinicaltrials.gov/study/NCT06114056
NCT06094777	A Study of HY-0102 in Patients With Advanced Solid Tumors	Drug: HY-0102	Shanghai YingLi Pharmaceutical Co. Ltd.	Phase 1	https://clinicaltrials.gov/study/NCT06094777
NCT06080854	AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer	Drug: Toripalimab Drug: Gemcitabine Drug: Nab paclitaxel Other: SBRT	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School The First Affiliated Hospital with Nanjing Medical University Fudan University Shanghai Changzheng Hospital The First Affiliated Hospital of Soochow University Xuzhou Central Hospital	Phase 2	https://clinicaltrials.gov/study/NCT06080854
NCT05990803	A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in the Treatment of Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies	Drug: BL-B01D1 Drug: SI-B003	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2	https://clinicaltrials.gov/study/NCT05990803
NCT06010303	A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma	Drug: LBL-007 Drug: Tislelizumab Drug: Chemotherapy Doublet	BeiGene	Phase 2	https://clinicaltrials.gov/study/NCT06010303
NCT06092762	A Phase II Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis	Drug: AK120	Akeso	Phase 2	https://clinicaltrials.gov/study/NCT06092762